Myeloid MKL1 Disseminates Cues to Promote Cardiac Hypertrophy in Mice

Li Liu1,2†, Qianwen Zhao2†, Lin Lin1†, Guang Yang3†, Liming Yu2, Lili Zhuo4*, Yuyu Yang1,5* and Yong Xu2,5

1 Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China, 2 Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Translational Medicine, Department of Pathophysiology, Nanjing Medical University, Nanjing, China, 3 Department of Pathology, Suzhou Municipal Hospital Affiliated with Nanjing Medical University, Suzhou, China, 4 Department of Geriatrics, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China, 5 Institute of Biomedical Research, Liaocheng University, Liaocheng, China

Cardiac hypertrophy is a key pathophysiological process in the heart in response to stress cues. Although taking place in cardiomyocytes, the hypertrophic response is influenced by other cell types, both within the heart and derived from circulation. In the present study we investigated the myeloid-specific role of megakaryocytic leukemia 1 (MKL1) in cardiac hypertrophy. Following transverse aortic constriction (TAC), myeloid MKL1 conditional knockout (MFCKO) mice exhibit an attenuated phenotype of cardiac hypertrophy compared to the WT mice. In accordance, the MFCKO mice were protected from excessive cardiac inflammation and fibrosis as opposed to the WT mice. Conditioned media collected from macrophages enhanced the pro-hypertrophic response in cardiomyocytes exposed to endothelin in an MKL1-dependent manner. Of interest, expression levels of macrophage derived miR-155, known to promote cardiac hypertrophy, were down-regulated in the MFCKO mice compared to the WT mice. MKL1 depletion or inhibition repressed miR-155 expression in macrophages. Mechanistically, MKL1 interacted with NF-κB to activate miR-155 transcription in macrophages. In conclusion, our data suggest that MKL1 may contribute to pathological hypertrophy via regulating macrophage-derived miR-155 transcription.

Keywords: transcriptional regulation, cardiac hypertrophy, macrophage, miRNA, NF-κB

INTRODUCTION

Heart failure is defined as irreversible or permanent loss of rhythmic contraction and relaxation of the myocardium rendering insufficient supply of blood and oxygen to peripheral organs and tissues (Gaetani et al., 2020). Heart failure is one of the leading causes of non-accidental deaths worldwide (Udelson and Stevenson, 2016). A host of pathologies, including hypertension, infection, diabetes, and congenital structural heart disease, can cause heart failure. Regardless of the etiologies, heart failure is almost invariably preceded by cardiac hypertrophy, a process morphologically seen as an expansion in cross-sectional area of cardiomyocyte (Liu and Molkentin, 2016; Zhao et al., 2020). At the transcriptional level, cardiac hypertrophy is characterized by the re-activation of fetal genes (e.g., β-MHC). Generally perceived as a compensatory response attempting to preserve heart function, heart failure is now recognized as a biological disease.
function under stress/injurious conditions, persistent hypertrophic response leads to maladaptation and eventually heart failure (Heineke and Molkentin, 2006).

Although the hypertrophic response takes place in the myocardium, it is hardly a cardiomyocyte-autonomous behavior. Instead, different cell types, including cardiac fibroblasts, endothelial cells, and circulating immune cells, contribute to the pathogenesis of pathological hypertrophy by forming cell-cell crosstalk with cardiomyocytes (Zhang et al., 2012; Frieler and Mortensen, 2015; Gogiraju et al., 2019). In addition, numerous humoral factors, originating from both intra-cardiac and extra-cardiac sources, act on the cardiomyocytes to regulate the pathogenesis of pathological hypertrophy by forming cell-endothelial cells, and circulating immune cells, contribute to pathological hypertrophy (Ranjan et al., 2019). MicroRNAs or miRNAs, a group of ~22 nt non-coding small RNAs, represent one of such factors (Patil et al., 2019; Dexheimer and Cochella, 2020). Transported via exosomes, miRNAs can transmit regulatory signals to cardiomyocytes from non-cardiomyocytes to regulate the hypertrophic response (Fan C. et al., 2020). Cardiac fibroblast derived miR-21-3p, for instance, promotes cardiomyocyte hypertrophy via targeting sorbin and SH3 domain-containing protein 2 (SORBS2) and PDZ and LIM domain 5 (PDLIM5) (Bang et al., 2014). Similarly, fibroblast derived miR-27a, miR-28-3p, and miR-34a promote oxidative stress, adverse cardiac remodeling, and heart failure in mice by targeting the antioxidant Nrf2 (Tian et al., 2018). On the contrary, a series of mesenchymal stem cell (MSC) derived miRNAs exert protective effects on cardiomyocytes to avert heart failure (Barile et al., 2014; Feng et al., 2014; Wang et al., 2015).

Megakaryocytic leukemia 1 (MKL1) is a transcriptional regulator with ubiquitous expression patterns (Wang et al., 2002). Developmentally redundant, MKL1 appears to play essential roles in a wide range of postnatal pathophysiological processes. MKL1 has been long considered as a key mechanosensor in various pathophysiological processes (Olson and Nordheim, 2010). Kuwahara et al. (2010) have reported that germine deletion of MKL1 in mice reduced the susceptibility to pressure overload induced cardiac hypertrophy. Further analysis revealed that MKL1 directly bound to the promoters of hypertrophic genes (e.g., atrial natriuretic peptide/ANP) in cultured cardiomyocytes in response to mechanical stretch and that MKL1 deficiency suppressed the expression of hypertrophic genes. Therefore, it was concluded that MKL1 might play a key role in the pathogenesis of pathological hypertrophy. However, whether the ability of MKL1 to regulate cardiac hypertrophy is cardiomyocyte-autonomous remains undetermined. In the present study, we report that MKL1 can contribute to the pathogenesis of cardiac hypertrophy by regulating myeloid-derived pro-hypertrophic cues.

**MATERIALS AND METHODS**

**Animals**

All the animal experiments were reviewed and approved by the intramural Ethics Committee on Humane Treatment of Experimental Animals. Myeloid-specific deletion of MKL1 was achieved by crossing the Mkl1<sup>−/−</sup> strain (Liu et al., 2018) with the LyzM-Cre strain, respectively (Yu et al., 2018). The offspring were designated based on genotyping: those with the Mkl1<sup>−/−</sup>; LyzM-Cre genotype (Cre positive) were called MFCKO and those with the Mkl1<sup>−/−</sup> genotype (Cre negative) were called WT. Pathological cardiac hypertrophy was induced in mice by the transverse aortic constriction (TAC) procedure as previously described (Yu et al., 2015). Cardiac functions were evaluated by echocardiography (GE Vivid 7 equipped with a 14-MHz phase array linear transducer, S12, allowing a 150 maximal sweep rate). Mice were anesthetized using 1.5% isoflurane. The body temperature was maintained at 37°C using a heating pad.

**Cell Culture, Plasmids, Transient Transfection, and Reporter Assay**

Murine macrophages RAW264.7 (ATCC) were maintained in DMEM supplemented with 10% FBS. Murine bone marrow-derived macrophages (BMDM) were isolated and cultured as described before (Yu et al., 2014). Neonatal rat ventricular myocytes (NRVM) were isolated and maintained as previously described (Yang et al., 2017). Endothelin (ET-1) was purchased from Peprotech. CCG-1423 (Chen et al., 2020a; Wu et al., 2020) and PDTC (Xu et al., 2017) were purchased from Selleck. MKL1 expression constructs and miR-155 promoter-luciferase constructs have been described previously (Basso et al., 2012; Thompson et al., 2013; Li et al., 2019c). Small interfering RNAs were purchased from Dharmacon. Transient transfection was performed with Lipofectamine 2,000. Cells were harvested 48 h after transfection and reporter activity was measured using a luciferase reporter assay system (Promega) as previously described (Yang et al., 2019a,b; Chen et al., 2020b,c; Li et al., 2020a).

**RNA Extraction and Real-Time PCR**

RNA was extracted using an RNaseasy RNA isolation kit (Qiagen) as previously described (Fan Z. et al., 2020). Reverse transcriptase reactions were performed using a SuperScript First-strand synthesis system (Invitrogen) as previously described (Yang et al., 2017). Endothelin (ET-1) was purchased from Peprotech. CCG-1423 (Chen et al., 2020a; Wu et al., 2020) and PDTC (Xu et al., 2017) were purchased from Selleck. MKL1 expression constructs and miR-155 promoter-luciferase constructs have been described previously (Basso et al., 2012; Thompson et al., 2013; Li et al., 2019c). Small interfering RNAs were purchased from Dharmacon. Transient transfection was performed with Lipofectamine 2,000. Cells were harvested 48 h after transfection and reporter activity was measured using a luciferase reporter assay system (Promega) as previously described (Yang et al., 2019a,b; Chen et al., 2020b,c; Li et al., 2020a).

**Histology**

Histological analysis was performed as previously described (Zhao et al., 2019; Dong et al., 2020; Li et al., 2020b). For immunofluorescence staining, antigen retrieval was performed by boiling the slides in sodium citrate (pH 6.0) for 1 min. The slides were washed 2 × 5 min in TBS plus 0.025% Triton X-100 with gentle agitation, blocked with 5% BSA,
and incubated with anti-CD45 (Abcam, 1:200) overnight. After several washes with PBS, the slides were incubated with FITC-labeled secondary antibodies (Jackson, 1:200) for 30 min. DAPI (Sigma) was added and incubated with cells for 5 min prior to observation. Immunofluorescence was visualized on a confocal microscope (LSM 710, Zeiss). For quantification, stain-positive cells were counted on each slide and normalized to the control group which is arbitrarily set as 1. Images were quantified with ∼10 fields counted per mouse.

**Chromatin Immunoprecipitation**

Chromatin Immunoprecipitation (ChIP) assays were performed essentially as described before (Fan Z. et al., 2019; Kong et al., 2019a,b; Li et al., 2019a,b,c,d,e; Liu et al., 2019; Lu et al., 2019; Shao et al., 2019; Weng et al., 2019; Sun et al., 2020). Briefly, chromatin was cross-linked with 1% formaldehyde. DNA was fragmented into ∼500 bp pieces using a Branson 250 sonicator. Aliquots of lysates containing 200 µg of protein were used for each immunoprecipitation reaction with anti-MKL1 (Santa Cruz, sc-32909), anti-acetyl H3 (Millipore, 06-599), anti-trimethyl H3K4 (Millipore, 07-473), anti-α-pyropin A (Santa, Cruz, sc-372), and anti-BRG1 (Santa Cruz, sc-10768). Precipitated genomic DNA was amplified by real-time PCR. A total of 10% of the starting material is also included as the input. Data are then normalized to the input and expressed as% of recovery.

**Statistical Analysis**

One-way ANOVA with post hoc Scheffe analyses were performed using an SPSS package. Unless otherwise specified, P-values smaller than 0.05 were considered statistically significant.

**RESULTS**

**MKL1 Deletion in Myeloid Cells Attenuates Pathological Cardiac Hypertrophy in Mice**

Macrophages play key roles in the pathogenesis of cardiac hypertrophy (Schiattarella and Hill, 2015). To evaluate whether MKL1 deficiency in macrophages would impact pathological hypertrophy, the TAC procedure was performed in myeloid conditional MKL1 knockout (MFCKO) mice and wild type (WT) littermates. The deletion of MKL1 in myeloid cells was confirmed by immunofluorescence staining of CD45+ cells showing that there were much fewer immune infiltrates in the MFCKO hearts than in the WT hearts (Figure 2D). On the other hand, qPCR analysis demonstrated that cardiac expression of pro-fibrogenic genes, including α-SMA (Figure 2E), collagen type I (Figure 2F), and collagen type III (Figure 2G), was down-regulated in the MFCKO mice compared to the WT mice. Picrosirius red staining (Figure 2H) and Masson's trichrome staining (Figure 2I) both confirmed that cardiac fibrosis was mitigated by myeloid-specific deletion of MKL1 in mice. Taken together, these data suggest that the pro-hypertrophic ability of MKL1 may originate from macrophages.

**MKL1 Deletion in Myeloid Cells Ameliorates Pressure Overload Induced Cardiac Inflammation and Fibrosis in Mice**

Next, we analyzed the effects of myeloid-specific MKL1 deletion on cardiac inflammation and cardiac fibrosis during the pathogenesis of cardiac hypertrophy in mice. Quantitative PCR showed that expression levels of pro-inflammatory cytokines, including IL-1β (Figure 2A), IL-6 (Figure 2B), and TNF-α (Figure 2C), were lower in the MFCKO mice than in the WT mice. Suppression of cardiac inflammation as a result of MKL1 loss in myeloid cells was confirmed by immunofluorescence staining of CD45+ cells showing that there were much fewer immune infiltrates in the MFCKO hearts than the WT hearts (Figure 2D). On the other hand, qPCR analysis demonstrated that cardiac expression of pro-fibrogenic genes, including α-SMA (Figure 2E), collagen type I (Figure 2F), and collagen type III (Figure 2G), was down-regulated in the MFCKO mice compared to the WT mice. Picrosirius red staining (Figure 2H) and Masson's trichrome staining (Figure 2I) both confirmed that cardiac fibrosis was mitigated by myeloid-specific deletion of MKL1 in mice. Taken together, these data suggest that the pro-hypertrophic ability of MKL1 may originate from macrophages.

**MKL1 Regulates a Pro-Hypertrophic Cue From Macrophages**

Having determined that macrophage MKL1 plays an essential role in the development of pressure overload induced pathological hypertrophy in mice, we hypothesized that an MKL1-dependent pro-hypertrophic cue may be transmitted from macrophages to cardiomyocytes. To this send, conditioned media (CM) were collected from cultured macrophages (RAW) and applied to freshly isolated neonatal rat left ventricular myocytes (NRVM) in the presence of ET-1, a potent pro-hypertrophic factor. The addition of macrophage CM enhanced the pro-hypertrophic effects of ET-1 as judged by the expression levels of ANP (Figure 3B), BNP (Figure 3C), and β-MHC (Figure 3D). MKL1 deletion (Figure 3A for knockdown efficiency) in macrophages, however, severely compromised the potency of the CM to potentiate ET-1 induced hypertrophy of NRVM. Similarly, pre-treatment of macrophages with CCG-1423, a small-molecule MKL1 inhibitor, significantly dampened the production of the pro-hypertrophic signal (Figures 3E–G). Finally, it was observed that CM collected from WT bone marrow...
FIGURE 1 | MKL1 deletion in macrophages attenuates pathological cardiac hypertrophy in mice. Myeloid-specific MKL1 knockout mice (MFCKO) and wild type (WT) littermates were subjected to the TAC procedure or the sham procedure. (A) Heart weight versus body weight. (B) Heart weight versus tibia bone length. (C) Left ventricular systolic diameter (LVSd) values. (D) Left ventricular posterior wall diameter (LVPWd) values. (E–G) Hypertrophic genes were measured by qPCR. (H) Cardiomyocyte cross-section areas were measured by wheat germ agglutinin (WGA) staining and quantified by Image J. (I) Ejection fraction (EF) values. (J) Fractional shortening (FS) values. N = 5–6 mice. Data represent mean ± SD. *p < 0.05, two-tailed t-test.
MKL1 deletion in macrophages ameliorates pressure overload induced cardiac inflammation and fibrosis in mice. MFCKO mice and WT mice were subjected to the TAC procedure. 

(A–C) Pro-inflammatory genes were measured by qPCR. 

(D) CD45 staining. 

(E–G) Pro-fibrogenic genes were measured by qPCR. 

(H) Picrosirius red staining. 

(I) Masson's trichrome staining, N = 5 mice for each group. Data represent mean ± SD. *p < 0.05, two-tailed t-test.
MKL1 Activates miR-155 Transcription

Heymans et al. (2013) have reported that macrophage-derived miR-155 is essential for the development of pressure overload induced pathological hypertrophy in mice. We therefore postulated that MKL1 might regulate miR-155 expression in macrophages. Indeed, miR-155 levels were decreased in the MFCKO hearts compared to the WT hearts (Figure 4A). Overexpression of MKL1 potentiated the induction of miR-155 expression by ET-1 treatment in RAW cells (Figure 4B). Next, endogenous MKL1 was silenced in RAW cells; MKL1 knockdown dampened the induction of miR-155 by ET-1 (Figure 4C). Likewise, inhibition of MKL1 activity by CCG-1423 suppressed derived macrophages (BMDMs) had a much stronger pro-hypertrophic effect than those from MKL1 KO BMDMs (Figures 3H–J).

**MKL1 Regulates miR-155 Expression in Macrophages**

FIGURE 3 | MKL1 regulates a pro-hypertrophic cue from macrophages. (A–D) RAW cells were transfected with siRNA targeting MKL1 or scrambled siRNA (SCR). Conditioned media were collected 48 h after transfection and applied to primary neonatal rat ventricular myocytes along with endothelin. Knockdown efficiencies were verified by qPCR and Western (A). ANP (B), BNP (C), and β-MHC (D) levels were examined by qPCR. (E–G) RAW cells were treated with or without CCG-1423 (10 µM) for 24 h. Conditioned media were collected 48 h after transfection and applied to primary neonatal rat ventricular myocytes along with endothelin. ANP (E), BNP (F), and β-MHC (G) levels were examined by qPCR. (H–J) Conditioned media were collected from WT and MFCKO bone marrow derived macrophages and applied to primary neonatal rat ventricular myocytes along with endothelin. ANP (E), BNP (F), and β-MHC (G) levels were examined by qPCR. Data represent mean ± SD. *p < 0.05, One-way ANOVA with post hoc Scheffe test.
FIGURE 4 | MKL1 regulates miR-155 expression in macrophages. (A) MFCKO mice and WT mice were subjected to the TAC procedure. miR-155 levels were examined by qPCR. N = 5 mice for each group. Data represent mean ± SD. *p < 0.05, two-tailed t-test. (B) RAW cells were transfected with MKL1 expression construct or an empty vector (EV) followed by treatment with endothelin. miR-155 levels were examined by qPCR. (C) RAW cells were transfected with siRNA targeting MKL1 or SCR followed by treatment with endothelin. miR-155 levels were examined by qPCR. (D) RAW cells were transfected with endothelin and CCG-1423. miR-155 levels were examined by qPCR. (E) BMDMs isolated from WT and MFCKO were treated with endothelin, miR-155 levels were examined by qPCR. Data represent mean ± SD. *p < 0.05, One-way ANOVA with post hoc Scheffe test.
the induction of miR-155 by ET-1 (Figure 4D). Comparison of miR-155 expression levels in WT BMDMs and MKL1 KO BMDMs confirmed that MKL1 played an essential role in regulating miR-155 expression in macrophages (Figure 4E).

**MKL1 Interacts With NF-κB to Activate miR-155 Transcription in Macrophages**

To investigate whether the regulation of miR-155 expression by MKL1 occurred at the transcriptional level, a miR-155 promoter-luciferase construct (-350/-1) was transfected into HEK293 cells. MKL1 over-expression dose-dependently activated the miR-155 promoter (Figure 5A), indicating that MKL1 may indeed directly regulate miR-155 transcription. Next, a series of truncated miR-155 promoter-luciferase constructs were transfected into HEK293 cells with or without MKL1 to determine the region where MKL1 may potentially bind. As shown in Figure 5B, MKL1 was able to activate the miR-155 promoter only in the presence of an intact NF-κB site. When the NF-κB site was mutated, MKL1 lost the ability to activate the miR-155 promoter (Figure 5C). ChIP assay demonstrated that there was significant MKL1 binding within the proximal miR-155 promoter surrounding the NF-κB site, which was further augmented by ET-1 treatment; in contrast, no appreciable MKL1 binding was detected on the distal miR-155 promoter (Figure 5D). Re-ChIP assay confirmed that a RelA-MKL1 complex was detectable on the proximal, but not the distal, miR-155 promoter (Figure 5E). Either RelA knockdown (Figures 5F,G) or RelA inhibition (Figure 5H) by a small-molecule compound (PDTCl) abrogated the binding of MKL1, suggesting that MKL1 may rely on NF-κB/RelA to be recruited to the miR-155 promoter. Of interest, MKL1 knockdown weakened the binding of RelA to the miR-155 promoter (Figure 5I). This was likely due to an altered chromatin structure because MKL1 deficiency reduced the levels of acetyl H3 (Figure 5J) and trimethyl H3K4 (Figure 5K) and abolished the recruitment of chromatin remodeling protein BRG1 (Figure 5L) on the miR-155 promoter. We thus conclude that interplay between MKL1 and NF-κB/RelA contributes to miR-155 transcription in macrophages.

**DISCUSSION**

Cell–cell crosstalk represents an important mechanism that guards the physiological and functional integrity of the heart but at the same time underlies the pathogenesis of cardiovascular diseases including pathological hypertrophy and heart failure (Tirziu et al., 2010). Traditionally, cardiac macrophages are thought to contribute to disturbances of cardiomyocyte function by producing/releasing inflammatory cytokines and reactive oxygen species. However, recent studies have found that macrophages may influence cardiomyocyte conductance and regeneration (Gomez et al., 2018). Here we report that MKL1 may indirectly regulate cardiomyocyte hypertrophy by controlling the production of a pro-hypertrophic cue (miR-155) in macrophages (Figure 6).

Kuwahara et al. (2010) have shown that mice with germ line deletion of MKL1 are resistant to pressure overload induced cardiac hypertrophy; it was not determined whether the ability of MKL1 to modulate the hypertrophic response is cardiomyocyte autonomous. A recent report showed that TAC-induced cardiac hypertrophy is equivalent in mice with a systemic deletion of MKL1 and a simultaneous cardiomyocyte conditional deletion of its closest sibling MKL2 (also known as MRTF-B) and in WT mice (Trembley et al., 2018). Unlike MKL2, MKL1 is dispensable for embryonic development (Oh et al., 2005; Sun et al., 2006). Although both MKL1 and MKL2 exhibit similar tissue/cell distribution, MKL1 has been reported to function as a much stronger transcriptional activator than MKL2 in cultured cells (Fang et al., 2011; Yang et al., 2013, 2014; Yu et al., 2014, 2017). It is not clear at this point how the loss of MKL1/MKL2 is tolerated during cardiac hypertrophy. One possibility is that myocardin, the founding member of the MRTF family, becomes hyperactivated and mediates pressure overload induced pathological hypertrophy (Xing et al., 2006).

Our data suggest that myeloid conditional MKL1 knockout (MFCKO) mice were more resistant to the development of cardiac hypertrophy than WT mice (Figure 1). This is consistent with our recent finding that myeloid MKL1, but not cardiomyocyte MKL1, contributes to cardiac ischemia-reperfusion injury in mice (Yu et al., 2018). This also strongly argues for the indispensable role of MKL1 in regulating macrophage phenotype and function to promote disease pathogenesis when combined with previous reports indicating that MKL1 contributes to colitis (Yu et al., 2014), atherosclerosis (Minami et al., 2012), and sepsis (Yu et al., 2017). We further demonstrate that MKL1 activated the transcription of miR-155, a macrophage-derived pro-hypertrophic cue (Heymans et al., 2013), by interacting with NF-κB/RelA. Again, this piece of evidence echoes previous findings, based on analysis of single gene expression (Fang et al., 2011; Yang et al., 2014; Chen et al., 2015) and genomewide expression (Xie, 2014; Yu et al., 2017), that transcription regulation by MKL1 in macrophage is often considered an extension of its interaction with NF-κB/RelA. Congruently, several reports suggest that NF-κB inhibition suppresses cardiac hypertrophy although a direct role of macrophage RelA has yet to be established in vivo (Andersen et al., 2012; Gaspar-Pereira et al., 2012). It should be pointed out that we do not propose miR-155 as the sole macrophage-derived, MKL1-dependent pro-hypertrophic cue. We have previously shown that MKL1 is a transcriptional activator of matrix metalloproteinase 9 (MMP9) in lung cancer cells (Cheng et al., 2015). Coincidently, macrophage-specific over-expression of MMP9 significantly exacerbates cardiac hypertrophy in mice (Toba et al., 2017). In addition, other transcriptional targets of MKL1 including inflammatory cytokines, chemokines, and oxidants may contribute to cardiac hypertrophy.

There are a few lingering issues that deserve further attention. First, although we propose that miR-155 derived from macrophages is directly regulated by MKL1 and may contribute to the pro-hypertrophic response in cardiomyocytes. An alternative scenario taking place in cardiomyocytes could equally contribute to cardiac hypertrophy because miR-155 is expressed and can be up-regulated by pro-hypertrophic stimuli in cardiomyocytes (Seok et al., 2014). It has also been
FIGURE 5 | MKL1 interacts with NF-κB to activate miR-155 transcription in macrophages. (A) A miR-155 promoter-luciferase construct was transfected into HEK293 cells with or without MKL1. Luciferase activities were normalized by both protein concentration and GFP fluorescence. (B) miR-155 promoter-luciferase constructs of various lengths were transfected into HEK293 cells with or without MKL1. Luciferase activities were normalized by both protein concentration and GFP fluorescence. (C) Wild type or NF-κB site mutant miR-155 promoter-luciferase construct was transfected into HEK293 cells with or without MKL1. Luciferase activities were normalized by both protein concentration and GFP fluorescence. (D) RAW cells were treated with endothelin and harvested at indicated time points. ChIP assays were performed with anti-MKL1. (E) RAW cells were treated with or without endothelin for 24h. Re-ChIP assays were performed with indicated antibodies. (F,G) RAW cells were transfected with siRNA targeting NF-κB or SCR followed by treatment with endothelin. Knockdown efficiencies and were verified by Western. ChIP assays were performed with anti-MKL1. (H) RAW cells were treated with endothelin and/or PDTC. ChIP assays were performed with anti-MKL1. (I–L) RAW cells were transfected with siRNA targeting MKL1 or SCR followed by treatment with endothelin. ChIP assays were performed with anti-RelA (I), anti-acetyl H3 (J), anti-H3K4Me3 (K), and anti-BRG1 (L). Data represent mean ± SD. *p < 0.05, One-way ANOVA with post hoc Scheffe test.
shown that ablation of miR-155 in cardiomyocytes appears to be sufficient to blunt the hypertrophic response induced by phenylephrine (PE) (Seok et al., 2014). This alternative model wherein MKL1 activates miR-155 transcription in cardiomyocytes to promote cardiac hypertrophy is certainly tempting in light of our recent report that cardiomyocyte-specific MKL1 deletion attenuates angiotensin II induced cardiac hypertrophy in mice (Wu et al., 2020). Second, the finding that MKL1 relies on NF-κB to regulate miR-155 transcription reinforces the notion that MKL1 and NF-κB are functionally interconnected given previous investigations linking these two factors in the pathogenesis of atherosclerosis (Fang et al., 2011), colitis (Yu et al., 2014), and septic shock (Yu et al., 2017). However, the precise role of NF-κB in the pathogenesis of cardiac hypertrophy has not been conclusively demonstrated especially in animal models likely due to the isoform-specific effects of NF-κB (Gordon et al., 2011). In addition, no direct evidence exists to demonstrate the influence of myeloid-specific NF-κB manipulation on cardiac hypertrophy. Therefore, our observation that MKL1 interacts with NF-κB to activate miR-155 transcription in macrophages cannot be construed as proof of myeloid NF-κB regulating cardiac hypertrophy. Instead, further investigations are needed to disentangle the functional overlap of NF-κB and MKL1 in regulating macrophage behavior and its implication in vivo.

In summary, we present evidence to show that myeloid MKL1 plays an essential role in the pathogenesis of cardiac hypertrophy. Previously, we have shown that endothelial MKL1 contributes to cardiac hypertrophy by activating ET-1 transcription (Weng et al., 2015a,b). These data collectively suggest that MKL1 regulates cardiac hypertrophy, at least in part, in a non-autonomous manner.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The animal study was reviewed and approved by the Nanjing Normal University Ethics Committee on Humane Treatment of Experimental Animals.

AUTHOR CONTRIBUTIONS

YY and LZ conceived the project. LLu, QZ, LLn, GY, and LY designed and performed experiments and collected and analyzed the data. YX wrote the manuscript. YY
and LZ secured funding and provided supervision. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the National Natural Science Foundation of China (81870326 and 81700211), Natural Science Foundation of the Jiangsu Higher Education Institutions of China (81870326 and 81700211), Natural Science Foundation of the Jiangsu Higher Education Institutions (20KJB310017), the Key Laboratory of Emergency and Trauma of Ministry of Education (Hainan Medical University) Ministry of Education (KLET-201914), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and Six Talent Peaks Project in Jiangsu Province.

**REFERENCES**

Andersen, N. M., Tang, R., Li, L., Javan, H., Zhang, X. Q., and Selzman, C. H. (2012). Inhibitory kappa-B kinase-beta inhibition prevents adaptive left ventricular hypertrophy. *J. Surg. Res.* 178, 105–109. doi: 10.1016/j.jss.2012.03.003

Bang, C., Batkai, S., Dangwal, S., Gupta, S. K., Foinquinos, A., Holzmann, A., et al. (2014). Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. *J. Clin. Invest.* 124, 2136–2146. doi: 10.1172/JCI70575

Barile, L., Lionetti, V., Cerviso, E., Matteucci, M., Gherghiceanu, M., Popescu, L. M., et al. (2014). Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. *Cardiovasc. Res.* 103, 530–541. doi: 10.1093/cvr/cvu167

Basso, K., Schneider, C., Shen, Q., Holmes, A. B., Setty, M., Leslie, C., et al. (2012). BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. *J. Exp. Med.* 209, 2455–2465. doi: 10.1084/jem.20121387

Chen, B., Fan, Z., Sun, L., Chen, J., Feng, Y., Fan, X., et al. (2020a). Epigenetic activation of the small GTPase TACE contributes to colorectal cancer cell migration and invasion. *Oncogenesis* 9:86. doi: 10.1038/s41389-020-00269-9

Chen, B., Yuan, Y., Sun, L., Chen, J., Yang, M., Yin, Y., et al. (2020b). MKL1 mediates TGF-β Induced RhoL transcription to promote breast cancer cell migration and invasion. *Front. Cell Dev. Biol.* 8:832. doi: 10.3389/fcell.2020.00832

Chen, B., Zhao, Q., Xu, T., Yu, L., Zhuo, L., Yang, Y., et al. (2020c). BRG1 activates PR65A transcription to regulate NO bioavailability in vascular endothelial cell. *Front. Cell Dev. Biol.* 8:774. doi: 10.3389/fcell.2020.00774

Chen, D., Yang, Y., Cheng, X., Fang, F., Xu, G., Yuan, Z., et al. (2015). Megakaryocytic leukemia 1 directs a histone H3 lysine 4 methylation complex to regulate hypoxic pulmonary hypertension. *Hypertension* 65, 831–839. doi: 10.1161/HYPERTENSIONAHA.114.04585

Cheng, X., Yang, Y., Fan, Z., Yu, L., Bai, H., Zhou, B., et al. (2015). MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription. *Oncogene* 34, 5570–5581. doi: 10.1038/onc.2015.14

Dexheimer, P. J., and Cochella, L. (2020). MicroRNAs: from mechanism to organism. *Front. Cell Dev. Biol.* 8:409. doi: 10.3389/fcell.2020.00409

Dong, W., Kong, M., Zhu, Y., Shao, Y., Wu, D., Lu, J., et al. (2020). Activation of TWIST1 transcription by chromatin remodeling protein brg1 contributes to liver fibrosis in mice. *Front. Cell Dev. Biol.* 8:340. doi: 10.3389/fcell.2020.00340

Fan, C., Zhang, E., Joshi, J., Yang, J., Zhang, J., and Zhu, W. (2020). Utilization of human induced pluripotent stem cells for cardiac repair. *Front. Cell Dev. Biol.* 8:36. doi: 10.3389/fcell.2020.00036

Fan, Z., Kong, M., Li, M., Hong, W., Fan, X., and Xu, Y. (2020). Brahma related gene 1 (Brg1) regulates cellular cholesterol synthesis by acting as a Co-factor for SREBP2. *Front. Cell Dev. Biol.* 8:259. doi: 10.3389/fcell.2020.00259

Fan, Z., Li, N., Xu, Z., Wu, J., Fan, X., and Xu, Y. (2019). An interaction between MKL1, BRG1, and C/EBPβ mediate palmitate induced CRP transcription in hepatocytes. *Biochim. Biophys. Acta Gene Regul. Mech.* 1862:194412. doi: 10.1016/j.bbagrm.2019.194412

Fang, F., Yang, Y., Yuan, Z., Gao, Y., Zhou, J., Chen, Q., et al. (2011). Myocardin-related transcription factor A mediates OxLDL-induced endothelial injury. *Circ. Res.* 108, 797–807. doi: 10.1161/CIRCRESAHA.111.240655

Feng, Y., Huang, W., Wani, M., Yu, X., and Ashraf, M. (2014). Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting MeCP2 via miR-22. *PLoS One* 9:e88685. doi: 10.1371/journal.pone.0088685

Frieler, R. A., and Mortensen, R. M. (2015). Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. *Circulation* 131, 1019–1030. doi: 10.1161/CIRCULATIONAHA.114.008788

Gordon, J. W., Shaw, J. A., and Kirshenbaum, L. A. (2011). Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. *Circ. Res.* 108, 1122–1132. doi: 10.1161/CIRCRESAHA.110.226928

Heineke, J., and Molkentin, J. D. (2006). Regulation of cardiac hypertrophy by intracellular signalling pathways. *Nat. Rev. Mol. Cell Biol.* 7, 589–600. doi: 10.1038/nrm1983

Heymans, S., Corsten, M. F., Verhesen, W., Carai, P., van Leeuwen, R. E., Custers, K., et al. (2013). Macrophage microRNA-155 promotes cardiac hypertrophy and failure. *Circulation* 128, 1420–1432. doi: 10.1161/CIRCULATIONAHA.112.013157

Kuwahara, K., Kinoshita, H., Kuwabara, Y., Nakagawa, Y., Usami, S., Minami, T., et al. (2010). Myocardin-related transcription factor A mediates OxLDL-induced endothelial injury. *Cell Death Dis.* 1:20. doi: 10.1038/cddis.2010.20

Li, N., Liu, S., Zhang, Y., Yu, L., Hu, Y., Wu, T., et al. (2020a). Transcriptional activation of matricellular protein Spondin2 (SPON2) by BRG1 in vascular endothelial cells promotes macrophage chemotaxis. *Front. Cell Dev. Biol.* 8:794. doi: 10.3389/fcell.2020.00794

Li, Z., Kong, X., Zhang, Y., Yu, L., Guo, J., and Xu, Y. (2020b). Dual roles of chromatin remodeling protein BRG1 in angiostatin II-induced endothelial-mesenchymal transition. *Cell Death Dis.* 11:549. doi: 10.1038/s41419-020-02744-y

Li, Z., Zhang, Y., Yu, L., Xiao, B., Li, T., Kong, X., et al. (2020c). BRG1 stimulates endothelial derived alarmin MRP8 to promote macrophage infiltration in an animal model of cardiac Hypertrophy. *Front. Cell Dev. Biol.* 8:569. doi: 10.3389/fcell.2020.00569

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.583492/full#supplementary-material
Li, Z., Chen, B., Dong, W., Kong, M., Fan, Z., Yu, L., et al. (2019a). MKL1 promotes endothelial-to-mesenchymal transition and liver fibrosis by activating TWIST1 transcription. Cell Death Dis. 10:899. doi: 10.1038/s41419-019-2101-4

Li, Z., Chen, B., Dong, W., Kong, M., Shao, Y., Fan, Z., et al. (2019b). The chromatin remodeler Brg1 integrates ROS production and endothelial-mesenchymal transition to promote liver fibrosis in mice. Front. Dev. Cell Biol. 7:245. doi: 10.3389/fcell.2019.00245

Li, Z., Li, P., Lu, Y., Sun, D., Zhang, X., and Xu, Y. (2019c). A non-autonomous role of MKL1 in the activation of hepatic stellate cells. Biochim. Biophys. Acta Gene Regul. Mech. 1862, 609–618. doi: 10.1016/j.bbagrm.2019.03.001

Li, Z., Lv, F., Dai, C., Wang, Q., Jiang, C., Fang, M., et al. (2019d). Activation of galecin-3 (LGALS3) transcription by injurious stimuli in the liver is commonly mediated by Brg1. Front. Cell Dev. Biol. 7:310. doi: 10.3389/fcell.2019.00310

Li, Z., Xia, J., Fang, M., and Xu, Y. (2019e). Epigenetic regulation of lung cancer cell proliferation and migration by the chromatin remodeling protein Brg1. Oncogenesis 8:66. doi: 10.3389/oncog.2019.00174-7

Liu, L., Mao, L., Wu, X., Wu, T., Liu, W., Yang, Y., et al. (2019). Brg1 regulates endothelial-derived IL-33 to promote ischemia-reperfusion induced renal injury and fibrosis in mice. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 2551–2561. doi: 10.1016/j.bbadis.2019.06.015

Liu, L., Wu, X., Xu, H., Yu, L., Zhang, X., Li, L., et al. (2018). Myocardin-related transcription factor A (MRTF-A) contributes to acute kidney injury by regulating macrophase ROS production. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 3109–3121. doi: 10.1016/j.bbadis.2018.05.026

Liu, R., and Molkentin, J. D. (2016). Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DSPUs). J. Mol. Cell Cardiol. 101, 44–49. doi: 10.1016/j.yjmcc.2016.08.018

Lu, Y., Lv, F., Kong, M., Chen, X., Duan, Y., Sun, D., et al. (2019). A CAb1-MRTF-A feedback loop contributes to hepatic stellate cell activation. Front. Cell Dev. Biol. 7:243. doi: 10.3389/fcell.2019.00243

Lv, F., Li, N., Kong, M., Wu, J., Fan, Z., Miao, D., et al. (2020). CDKN2a/p16 antagonizes hepatic stellate cell activation and liver fibrosis by modulating ROS levels. Front. Cell Dev. Biol. 8:176. doi: 10.3389/fcell.2020.00176

Mao, L., Liu, L., Zhang, T., Qin, H., Wu, X., and Xu, Y. (2020). Histone deacetylase 11 contributes to renal fibrosis by repressing KLF15 transcription. Front. Cell Dev. Biol. 8:235. doi: 10.3389/fcell.2020.00235

Minami, T., Kuwahara, K., Nakagawa, Y., Takaoka, M., Kinosita, H., Nakao, K., et al. (2012). Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. EMBO J. 31, 4428–4440. doi: 10.1038/emboj.2012.296

Oh, J., Richardson, A. J., and Olson, E. N. (2005). Requirement of myocardin-related transcription factor-B for remodeling of branial arch arteries and smooth muscle differentiation. Proc. Natl. Acad. Sci. U.S.A. 102, 15122–15127. doi: 10.1073/pnas.0507346102

Ohlsson, E. N., and Noedheim, A. (2010). Linking actin dynamics and gene transcription to drive cellular motile functions. Nat. Rev. Mol. Cell Biol. 11, 353–365. doi: 10.1038/nrm32890

Patil, M., Henderson, J., Luong, H., Annamalai, D., Sreekrit, G., and Krishnamurthy, P. (2019). The art of intercellular wireless communications: exosomes in heart disease and therapy. Front. Cell Dev. Biol. 7:315. doi: 10.3389/fcell.2019.00315

Ranjan, P., Kumari, R., and Verma, S. K. (2019). Cardiac fibroblasts and cardiac related transcription factors is required for cardiomyocyte integrity in loaded-induced ventricular hypertrophy. Circulation 138, 1864–1878. doi: 10.1161/CIRCULATIONAHA.117.031788

Udelson, J. E., and Stevenson, L. W. (2016). The future of heart failure diagnosis. Therapy, and Management. Circulation 133, 2671–2686. doi: 10.1161/CIRCULATIONAHA.116.023518

Wang, D. Z., Li, S., Hockemeyer, D., Sutherland, L., Wang, Z., Schratt, G., et al. (2002). Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc. Natl. Acad. Sci. U.S.A. 99, 14855–14860. doi: 10.1073/pnas.222561499

Wang, Y., Zhang, L., Li, Y., Chen, L., Wang, X., Guo, W., et al. (2015). Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. Int. J. Cardiol. 192, 61–69. doi: 10.1016/j.ijcard.2015.05.020

Weng, X., Yu, L., Liang, P., Chen, D., Cheng, X., Yang, Y., et al. (2015a). Endothelial MRTF-A mediates angiotensin II induced cardiac hypertrophy. J. Mol. Cell Cardiol. 80, 23–33. doi: 10.1016/j.yjmcc.2014.11.009

Weng, X., Yu, L., Liang, P., Li, L., Dai, X., Zhou, B., et al. (2015b). A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy. J. Mol. Cell Cardiol. 82, 48–58. doi: 10.1016/j.yjcrc.2015.02.010

Weng, X., Zhang, Y., Li, Z., Yu, L., Xu, F., Fang, M., et al. (2019). Class II transactivator (CIITA) mediates IFN-gamma induced eNOS repression by elevating SVE39H1. Biochim. Biophys. Acta Gene Regul. Mech. 1862, 163–172. doi: 10.1016/j.bbagrm.2019.01.005

Wu, T., Wang, H., Xin, X., Yang, J., Hou, Y., Fang, M., et al. (2020). An MRTF-A-S1-PDEx axis mediates angiotensin-II-induced cardiac hypertrophy. Front. Cell Dev. Biol. 8:839. doi: 10.3389/fcell.2020.00839

Xie, L. (2014). MKL1/2 and ELK4 co-regulate distinct serum response factor (SRF) transcription programs in macrophages. BMC Genomics 15:301. doi: 10.1186/1471-2164-15-301

Xing, W., Zhang, T. C., Cao, D., Wang, Z., Antos, C. L., Li, S., et al. (2006). Myocardin induces cardiomyocyte hypertrophy. Circ. Res. 98, 1089–1097. doi: 10.1161/01.RES.0000218781.23443.3e

Xu, W., Xu, H., Fang, M., Wu, X., and Xu, Y. (2017). MKL1 links epigenetic activation of MMP2 to ovarian cancer cell migration and invasion. Biochem. Biophys. Res. Commun. 487, 500–508. doi: 10.1016/j.bbrc.2017.04.006

Yang, G., Weng, X., Zhao, Y., Zhang, X., Hu, Y., Dai, X., et al. (2017). The histone H3K9 methyltransferase SVE39H1 links SIRT1 repression to myocardial infarction. Nat. Commun. 8:14941. doi: 10.1038/s41419-014941

Yang, Y., Chen, D., Yuan, Z., Fang, F., Cheng, X., Xia, J., et al. (2013). Megakaryocytic leukemia 1 (MKL1) ties the epigenetic machinery to hypoxia-induced transactivation of endothelin-1. Nucleic Acids Res. 41, 6005–6017. doi: 10.1093/nar/gkt311

Yang, Y., Cheng, X., Tian, W., Zhou, B., Wu, X., Hu, H., et al. (2014). MRTF-A steers an epigenetic complex to activate endothelin-induced pro-inflammatory transcription in vascular smooth muscle cells. Nucleic Acids Res. 42, 10460–10472. doi: 10.1093/nar/gkt776
Y. Yang, Z. Li, J. Guo, and Y. Xu. (2020). Deacetylation of MRTF-A by SIRT1 defies senescence induced down-regulation of collagen type I in fibroblast cells. *Biochim. Biophys. Acta Mol. Basis Dis.* 1866:165723. doi: 10.1016/j.bbadis.2020.165723

Y. Yang, L. Liu, M. Fang, H. Bai, and Y. Xu. (2019a). The chromatin remodeling protein BRM regulates the transcription of tight junction proteins: Implication in breast cancer metastasis. *Biochim. Biophys. Acta Gene Regul. Mech.* 1862, 547–556. doi: 10.1016/j.bbagrm.2019.03.002

Y. Yang, L. Liu, M. Cheng, M. Fang, Q. Zeng, et al. (2019b). The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis. *Biochim. Biophys. Acta Gene Regul. Mech.* 1862, 834–845. doi: 10.1016/j.bbagrm.2019.05.005

Y. Yu, F. Wang, X. Dai, X. Hu, Q. Xi, M. Fang, et al. (2017). MKL1 defines the H3K4Me3 landscape for NF-κB dependent inflammatory response. *Sci. Rep.* 7:191. doi: 10.1038/s41598-017-00301-w

Y. Yu, L. Weng, X. Liang, P. Dai, X. Wu, X. Hu, et al. (2014). MRTF-A mediates LPS-induced pro-inflammatory transcription by interacting with the COMPASS complex. *J. Cell Sci.* 127, 4645–4657. doi: 10.1242/jcs.152314

Y. Yu, G. Yang, X. Weng, X. Liang, L. Li, L. Li, et al. (2015). Histone methyltransferase SET1 mediates angiotensin ii-induced endothelin-1 transcription and cardiac hypertrophy in mice. *Arterioscler Thromb. Vasc. Biol.* 35, 1207–1217. doi: 10.1161/ATVBAHA.115.305230

Y. Yu, G. Yang, X. Zhang, P. Wang, X. Weng, Y. Yang, et al. (2018). Megakaryocytic Leukemia 1 (MKL1) bridges epigenetic activation of NADPH oxidase in macrophages to cardiac ischemia-reperfusion injury. *Circulation* 138, 2820–2836. doi: 10.1161/CIRCULATIONAHA.118.035377

P. Zhang, J. Su, and U. Mende. (2012). Cross talk between cardiac myocytes and fibroblasts: from multiscale investigative approaches to mechanisms and functional consequences. *Am. J. Physiol. Heart Circ. Physiol.* 303, H1385–H1396. doi: 10.1152/ajpheart.01167.2011

M. Zhao, T. Ye, S. Su, J. and V. Garç. (2020). Cardiomyocyte proliferation and maturation: two sides of the same coin for heart regeneration. *Front. Cell Dev. Biol.* 8:594226. doi: 10.3389/fcell.2020.594226

Q. Zhao, J. Yang, H. Chen, J. Li, L. Que, L. Zhu, et al. (2019). Pel1 induction impairs cardiac microvascular endothelium through Hsp90 dissociation from IRE1α. *Biochim. Biophys. Acta Mol. Basis Dis.* 1865, 2606–2617. doi: 10.1016/j.bbadis.2019.06.017

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Liu, Zhao, Lin, Yang, Yu, Zhuo, Yang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.